Elizabeth Whittington

Picato OK'ed to treat precancerous skin lesions.

Updates from the American Society of Clinical Oncology meetings on genitourinary and gastrointestinal cancers.

Research was presented at the ASCO Genitourinary Cancers Symposium, including advancements in prostate cancer.

Regorafenib shows to extend survival in metastatic colorectal cancer.

GA101 could be the next step for patients who relapse on Rituxan (rituximab), a current standard of therapy.

In an early-phase study, PCI-32765, a BTK inhibitor, was shown to work against CLL, a type of non-Hodgkin lymphoma.

Patients who are not suffering from symptoms of nonbulky follicular lymphoma are better off waiting until symptoms occur before beginning chemotherapy instead of undergoing maintenance Rituxan.

A novel drug called ponatinib that targets the BCR-ABL mutation overcomes a mutation that has been resistant to all previous approved therapies.

A drug removed from the market last year to treat acute myeloid leukemia may have a second life.

With the approval of Adcetris (brentuximab vedotin) for relapsed Hodgkin lymphoma, researchers are now examining whether the drug will help newly diagnosed patients.

Research updates from the annual San Antonio Breast Cancer Symposium and American Society of Hematology.

IHadCancer.com is a social networking site for those affected by cancer.

A new study published in The Lancet shows that one group could reduce their risk of colorectal cancer from taking the pill on a daily basis.

Afinitor (exemestane) and an aromatase inhibitor delay cancer growth in metastatic breast cancer.

A phase 3 randomized trial of two hormone therapies showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

Women receiving a supportive care drug to reduce bone loss caused by breast cancer treatment may actually be getting more than that—improved survival and lower risk of metastatic recurrence.